Skip to main content

Table 1 Overall baseline characteristics according to SVR status

From: Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study

Parameters Overall
(n = 985)
SVR
(n = 966)
No SVR
(n = 19)
Sex, n (%)
 M 543 (55.1) 529 (54.8) 14 (73.7)
 F 442 (44.9) 437 (45.2) 5 (26.3)
Age, years, median [IQR] 67 [59–73] 67 [59–73] 66 [60–71]
BMI, kg/m2, median [IQR] 26 [24–28.4] 26 [24–28.3] 27 [23.3–30.6]
Diabetes, n (%) 131 (13.3) 129 (13.4) 2 (10.5)
Metabolic syndrome, n (%) 69 (8) 69 (8.1)
Liver disease stage, n (%)
 Advanced fibrosis 254 (25.8) 252 (26.1) 2 (10.5)
 Cirrhosis 731 (74.2) 714 (73.9) 17 (89.5)
HCV genotype, n (%)
 1 765 (77.7) 754 (78.1) 12 (63.2)
 2 160 (16.2) 155 (16.1) 4 (21.1)
 3 50 (5.1) 47 (4.9) 3 (15.8)
 4 10 (1.0) 10 (1.0) 0
Liver stiffness, kPa, median [IQR] 17.3 [11.9–35.3] 16 [11.8–23] 23.4 [14.6–41.7]
Treatment duration, n (%) (weeks)
 12 612 (62.1) 603 (62.4) 9 (47.4)
 24 373 (37.9) 363 (37.6) 10 (52.6)
SVR12, n (%) 966 (98.1)   
DAAs regimen, n (%)
 SOF/RBV (dual) 417 (42.3) 408 (42.2) 10 (52.6)
 SOF/LDV ± RBV 183 (18.6) 186 (19.3) 3 (15.8)
 SOF/DCV ± RBV 39 (4.0) 33 (3.4) 0 (0.0)
 SOF/SIM ± RBV 99 (10.1) 97 (10) 2 (10.5)
 2D/3D ± RBV 247 (25.0) 242 (25.1) 4 (21.1)
Treatment classes, n (%)
 SOF based 738 (74.9) 723 (74.8) 15 (78.9)
 RBV included 705 (71.6) 693 (71.7) 12 (63.2)
 SOF/RBV (all) 573 (58.2) 561 (58.1) 12 (63.2)
HCC occurrence, n (%) 35 (3.6) 35 (3.6) 0 (0)